PHILADELPHIA, PA — Carisma Therapeutics Inc. (Nasdaq: CARM) is set to present significant advancements in cancer treatment at the Society for Immunotherapy of Cancer (SITC) 2024 conference in Houston, Texas, from November 6 to 10. The company’s poster presentations will spotlight promising pre-clinical and clinical research focused on innovative therapies for challenging cancer types.
On display will be the pre-clinical efficacy of a novel anti-GPC3 chimeric antigen receptor macrophage (CAR-M) targeting hepatocellular carcinoma. This research, publication number 329, will be presented on Friday, November 8, at Exhibit Halls A and B of the George R. Brown Convention Center.
Additionally, Carisma will unveil a Phase 1, first-in-human study of autologous monocytes engineered to express an anti-HER2 CAR. This study targets HER2 overexpressing solid tumors and carries publication number 659. It will also be presented on November 8 at the same location.
These pioneering studies highlight Carisma’s efforts to advance immunotherapy and improve outcomes for cancer patients. The posters will be accessible online in the “Publications” section of Carisma’s website once the sessions commence, providing broader access to these groundbreaking findings.
For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News and MSN.